Abstract:Background: Threats by enforced Intellectual Property (IP) rights to equitable HIV treatment access by poor populations are impending. India and China's policy directions in the field will be crucial in ultimately affecting the affordability and accessibility of antiretroviral (ARV) therapy in the under-served markets. These directions, together with the exploitation level of IP-bound flexibilities and the evolutionary modelling in partnerships and trade agreements between research-based and generic pharmaceutical industry, will also affect the outcomes of self-sufficiency efforts now at their beginning in the developing world as far as domestic manufacturing of generic ARV drugs is concerned. Aims: This paper explores key issues, implications and interaction dynamics across these challenging scenarios while attempting to provide equitable solution glimpses into the near future. Results: Access-oriented long-term drug policy strategies entitled to pass muster of governments, research-based as well as generic industries in both developed and developing countries are needed if equitable access to affordable ARV treatments by poor people has to be achieved despite enforced IP rights. Predictable dynamics between western multinationals and transitional country generic corporations let regard IP-bound Voluntary License flexibilities as a fitting measure into just mentioned needs especially if substantial incentives to generic corporations are concurrently secured. Efforts to equitably expand ARV drug access through exploiting IP opportunities should encompass attainment of self-sufficiency in domestic drug manufacturing whenever basic requirements are in place in the developing world as a whole. A credible industrial potential would act, indeed, as a boosting factor for drawing branded drug producers into technology transfer agreements, the terms of which would let all contractors enjoy substantial advantages. These perspectives consistently bind up with the foreseeable long-term trade and drug policy directions of India and China according to frontier crossing implications of their key IP management trends as well as their multifaceted penetration strategies of both the wealthy and under-served markets worldwide. As coherent with these perspectives, more disbursement by wealthy country governments and donors to basic infrastructure development in sub-Saharan African nations with stable governments in place is urged both as a priority for improving Africa's economy and a prerequisite for allowing domestic industrial plants to take off. Aiming at the targets just underscored, WHO's brokering role in negotiated agreements between wealthy and developing country-based firms as well as its technical guidance in setting international standards have always to be sought if equitable and appropriate end results are to be attained. Conclusion: Overall insights in this paper would mean that, while research-based corporations are to be praised whenever waiving, on humanitarian purposes, part of their profits, the trade and profit rules cannot basically be given up if long-term sustainable results are the goal to look for. Only negotiated agreements securing all contracting parties lasting advantages may ensure shifting of such a goal from mere vision to a really sustainable attainment.

Pharmaceutical corporate power, traditional medical knowledge, and intellectual property governance in China

On the Research of the Construction of the Intellectual Property Protection System for Collaborative Innovation---From the Perspective of Knowledge Spillover

Pharmaceutical Industry in China: Policy, Market and IP

Creating Knowledge Assets under Biocapitalism: Analyzing China's Biomedical Industry and Its Patent Networks

The Limits to Law: How Intellectual Properties Are Used and Protected in Chinese Industries

TRIPS-plus and Access to Medicines in China.

The Evolution of China's IPR System and Its Impact on the Patenting Behaviours and Strategies of Multinationals in China.

Challenges faced by the Indian Pharmaceutical Companies in protecting various forms of Intellectual Property Rights

Game-theoretic analysis of governance and corruption in China's pharmaceutical industry

Intellectual Property Protection And Firm Strategy In The China Integrated Circuit Industry

PHARMACEUTICAL INDUSTRY DEVELOPMENT: KEY POLICY INSTRUMENTS IN CHINA

The Protection of Intellectual Property Rights: the Core Strategy for Global Development of Traditional Chinese Medical Industry in the 21st Century

China’s intellectual property rights provocation: A political economy view

The Tale of Viagra Patents: Comparative Studies of the Global Challenges in China and Other Countries

Revolutionizing pharmaceutical innovation: Unveiling the impact of endogenous knowledge spillover in China

Introduction and Profound Consideration on Intellectual Property Rights Protection Standard Terms Relat-ed to Drugs beyond the Regulations of TRIPS

Analysis of Medicine-related Issues in New "patent Law"

Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?

Rethinking Test Data Protection in China-US Trade War: Integrating Empirical and Normative Analysis

Policy selection of regulatory data protection under the background of drug innovation strategy in China

Patents, trade and medicines: past, present and future